论文部分内容阅读
目的：：探讨羧甲司坦联合布地奈德治疗哮喘的临床疗效及对血清炎症因子的影响。方法：186例哮喘患者随机分为观察组(93例)和对照组(93例),对照组于常规治疗基础上给予布地奈德治疗,观察组患者于对照组治疗基础上给予羧甲司坦治疗,1周为一个疗程。观察两组患者疗效。应用初期呼吸阻力( Rrsc)和莱斯特咳嗽问卷( LCQ)分别评估气道反应性及患者咳嗽状况,观察患者日、夜间症状改善；检测血清炎症因子水平,并评估其安全性。结果：治疗后两组LCQ 评分较前明显升高, Rrsc、日、夜间症状评分,及血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)和IgE水平则均较前显著下降(P0.05)。结论：羧甲司坦联合布地奈德治疗哮喘能够显著改善患者哮喘症状,咳嗽减轻,炎症因子降低,且具有较高的安全性。“,”Objective:To explore the clinical efficacy and the effects on serum inflammatory factors of carbocisteine and budes-onide in the treatment of asthma. Methods:Totally 186 asthma patients were randomly divided into the observation group (93 cases) and the control group (93 cases). The control group received budesonide combined with the conventional treatment, the observation group was treated with carbocisteine and budesonide, and one week was a treatment course. The efficacy was observed. The airway re-sponsiveness and cough condition was respectively assessed by early respiratory resistance ( Rrsc) and Leicester cough questionnaire ( LCQ) . The improvement of day and night symptoms was observed, and the serum levels of inflammatory factors and the safety were also evaluated. Results:LCQ score of the observation group after the treatment was significantly higher than that of the control group, Rrsc score for day and night symptoms and serum IL-8, TNF-αand IgE levels were significantly lower than those in the control group, and the differences were statistically significant (P0. 05). The difference in the in-cidence of ADR between the groups was not statistically significant (P>0. 05). Conclusion: Carbocisteine and budesonide in the treatment of asthma can significantly improve asthma symptoms and reduce cough and inflammatory cytokines with promising safety.